Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of tuvusertib combinations after PARP inhibitor progression in epithelial ovarian cancer
MOH_2024-10-06_013677Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tuvusertib, niraparib and lartesertib in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (3 arms), sponsored by Merck KGaA. Started Jul 2024; status: completed.
02
Drugs
tuvusertibnirapariblartesertib
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on MOH_2024-10-06_013677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-10-06_013677.